Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACHIEVE - An Adaptive Trial of the Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)

Next Previous
X
Search
Trial Profile

ACHIEVE - An Adaptive Trial of the Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TCB 008 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms ACHIEVE; ACHIEVE UK
  • Sponsors TC BioPharm

    • Most Recent Events

    • 13 Feb 2025 According to a TC BioPharm media release, the company has concluded dosing of Cohort A patients in the ACHIEVE Phase 2B UK clinical trial. Recruitment into Cohort B continues.
    • 10 Feb 2025 According to a TC BioPharm media release, the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, has completed the full dosing regiment, and is expected to receive an additional fifth dose. Enrolment of a second Cohort B patient has also been initiated. The company expect to complete enrolment in the second cohort in the first half of 2025, with data readout anticipated later this year.
    • 20 Dec 2024 According to a TC BioPharm media release, company announced 3 patients have now completed the full-dose regimen in the ACHIEVE Phase 2b trial in the UK with no drug-related Adverse Events seen in any of the restart patients. Company look forward to continued success with recruitment and preliminary data from the ACHIEVE study in 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top